SENSIBIO 30® g. NEW PACKAGE

09/11/2020|All articles, Product launches|

IASIS PHARMA, consistently aware of its responsibility to serve at the highest possible level both health care professionals and patients, introduces to the pharmaceutical market Sensibio® in 30 g. new package. Sensibio® 30 g. new package was launched to the market in order to complete Sensibio® 15 g., the well-established fixed combination of Fusidic acid (antibiotic) and [...]

FLUSTERIX® 30 g. NEW PACKAGE

09/11/2020|All articles, Product launches|

IASIS PHARMA, consistently aware of its responsibility to serve at the highest possible level both health care professionals and patients, introduces to the pharmaceutical market Flusterix® in 30 g. new package. Flusterix® 30 g. was launched in order to complete the, well-established to the pharmaceutical market, Flusterix® 15 g. package. Flusterix® has Fusidic acid as its active ingredient, [...]

GLUCOFREE® & GLUCOPLUS® PRESS RELEASE

04/06/2019|All articles, Product launches|

IASIS PHARMA proudly announces the addition of Glucofree® & Glucoplus® to its wide product portfolio. Glucofree® & Glucoplus® have metformin hydrochloride as their active ingredient and they belong to OHAs (Oral Hypoglycemic Agents). Metformin’s therapeutic indication is type 2 diabetes, especially on obese patients when the imposed diet and body exercise are not enough to [...]

MAG-IASIS® PRESS RELEASE

22/01/2018|All articles, Product launches|

IASIS PHARMA announces the launch of MAG-IASIS®, the first uniquely effective combination indicated for magnesium deficiency in the form of effervescent tablets. Each effervescent tablet of MAG-IASIS® contains: 1193.57 mg magnesium citrate & 667.56 mg magnesium aspartate equivalent to 243 mg Magnesium. MAG-IASIS® main indications are: ● magnesium deficiency, under the condition that it cannot [...]

ZALEPIN® RAPID PRESS RELEASE

03/01/2018|All articles, Product launches|

IASIS PHARMA has launched a new pharmaceutical product under the brand name of ZALEPIN® RAPID, enriching its CNS product portfolio. ZALEPIN® RAPID contains Olanzapine as its active ingredient and belongs to the class of atypical antipsychotic agents, the newer generation of antipsychotics. ZALEPIN® RAPID is available in the form of orodispersible tablets (ODT), offering the [...]

RAMI-AMLO® PRESS RELEASE

15/03/2017|All articles, Product launches|

IASIS PHARMA announces the launch of the original antihypertensive pharmaceutical product under the brand name of Rami-Amlo®. The product is a fixed-dose combination of an Angiotensin Converting Enzyme (ACE) Inhibitor with a Calcium Channel Blocker. Each Rami-Amlo® capsule, contains the active ingredients Ramipril & Amlodipine, combined in a single dosage form, in 4 strengths: 5mg [...]

Relief® caps NEW PACK SIZE PRESS RELEASE

26/04/2016|All articles, Product launches|

IASIS PHARMA consistently aware of its responsibility to serve at the highest possible level the health care professionals and the patients is introducing in the pharmaceutical market the new pack of 30 caps of Relief® in order to fully comply with the Greek and International Guidelines. Relief® caps BTx30 pack size is an important addition [...]

LICOSIL PRESS RELEASE

08/09/2014|All articles, Product launches|

Pharma Q, a member of IASIS PHARMA group of companies, has launched a new pharmaceutical product under the brand name Licosil (Sildenafil) to treat erectile dysfunction. Licosil is the 1st generic sildenafil, which has been successfully launched in the Greek pharmaceutical market by a Greek pharmaceutical industry in τwο strengths: 50 and 100 mg respectively [...]

LARTOKAZ PRESS RELEASE

19/05/2014|All articles, Product launches|

IASIS PHARMA has launched a new pharmaceutical product under the brand name Lartokaz.  It is an Irbesartan/hydrochlorothiazide combination preparation in two strengths: (150+12,5)mg/tab and (300+12,5)mg/tab respectively. Irbesartan is an angiotensin II receptor antagonist used mainly for the treatment of hypertension and in a combination formulation with hydrochlorothiazide(diuretic), is able to achieve an additive antihypertensive effect.

RABEREN/ΙΑSIS PRESS RELEASE

28/04/2014|All articles, Product launches|

IASIS PHARMA has launched a new pharmaceutical product under the brand name Raberen (as rabeprazole sodium). Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. Raberen in either 10 or 20 mg form of gastro-resistant tablets, is the 1st generic rabeprazole, which has been successfully launched in the Greek pharmaceutical market by [...]

Load More Posts